drugset / Trial / NCT02079766

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

NCT02079766

Phase 2 Completed 41 enrolled Avid Radiopharmaceuticals
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.

Timeline

Start
2014-06
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir F18 Diagnostic / imaging agent 370 mbq Intravenous
Subject florbetapir F 18 Diagnostic / imaging agent 370 mbq Intravenous

Indications